Last week, Apple revealed it was working with Eli Lilly on detecting dementia in its early stages — and now a co-author of the study is reportedly heading to the Bill and Melinda Gates Foundation.

The scientist, Andrew Trister, joined Apple in April 2016 in a ‘special projects’ role — before the tech giant’s big ambitions in health care were thrust into the spotlight.

In an interview with CNBC on Friday, Trister confirmed he was departing to take on the role of digital health innovation at the Gates Foundation — where he is set to work with entrepreneurs that are thinking of bringing digital health technologies from the United States to developing nations, where smartphones are increasingly becoming all-pervasive. In addition, he will also invest in projects located under-resourced regions, such as rural Africa and India, the report said.

Remember when Retrophin disclosed in June that it’s finally settled up the four-year legal saga with founder and former CEO Martin Shkreli? In an update for investors on Wednesday, the company added that it had paid an undisclosed sum to the infamous biotech exec and financier as part of the agreement — though it won’t say how much.

Shkreli, who’s serving a 7-year prison sentence for defrauding investors of his hedge funds, had “agreed to extinguish his rights to future advancement of legal fees and indemnification by the company (other than for certain pending litigation), and to abide by certain standstill restrictions,” the company added in a 10-Q filing first reported by CNBC.

Two years ago, Kåre Schultz took on the gargantuan challenge of fixing a financially troubled, debt-laden Teva with a sparse pipeline. He responded by initiating a sweeping restructuring by cutting thousands of jobs, executing facility closures, trimming board compensation and overhauling the Isreal-based company’s senior executive team. One of his moves was to officially promote Michael McClellan to chief financial officer. Along with its second-quarter results on Wednesday, Teva said McClellan was departing for personal reasons.

In a recent chronicle on the promise and price of cell therapies, Siddhartha Mukherjee — author, oncologist and Columbia professor among his other titles — mused about how engineered T cells had blurred the traditional boundaries separating a procedure and a drug. “Procedures come alive in the tinkering, fussing hands of their operators,” he observed, while a “drug, in contrast, is a depersonalized entity.” For the new generation of meticulously manufactured CAR-T to reach the masses, innovators must marry the iterative nature of a procedure with the production efficiency of a drug — and add a ruthless pursuit of the leanest, cheapest process possible.